✦ LIBER ✦

Autoantibodies against insulin and β-islet cells in pancreatic adenocarcinoma: A possible explanation for diabetes mellitus

✍ Scribed by Konstantinos N. Syrigos; Manousos M. Konstantoulakis; Ioannis Fyssas; Nikolaos Katsilambros; Basilios C. Golematis

Publisher: John Wiley and Sons
Year: 1996
Tongue: French
Weight: 387 KB
Volume: 66
Category: Article
ISSN: 0020-7136
DOI: 10.1002/(sici)1097-0215(19960529)66:5<624::aid-ijc7>3.0.co;2-v

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Islet cell and insulin autoantibodies in

Islet cell and insulin autoantibodies in subjects at high risk for development of Type 1 (insulin-dependent) diabetes mellitus: the Lyon family study

✍ Ch. Thivolet; B. Beaufrére; H. Bétuel; L. Gebuhrer; P. Chatelain; A. Durand; J. 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 748 KB

Genetic determination as well as prospective analysis of islet cell autoantibodies and autoantibodies to insulin were conducted in a population of 479 first degree relatives of 174 Type 1 (insulin-dependent) diabetic patients. Analysis of HLA haplotypes within families illustrated the high frequency

Hyperglycemia and hyperinsulinemia have

Hyperglycemia and hyperinsulinemia have additive effects on activation and proliferation of pancreatic stellate cells: Possible explanation of islet-specific fibrosis in type 2 diabetes mellitus

✍ Oak-Kee Hong; Seung-Hwan Lee; Marie Rhee; Seung-Hyun Ko; Jae-Hyoung Cho; Yoon-He 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 301 KB

Islet cell and insulin autoantibodies in

Islet cell and insulin autoantibodies in organ-specific autoimmune patients. Their behaviour and predictive value for the development of Type 1 (insulin-dependent) diabetes mellitus. A 10-year follow-up study

✍ C. Betterle; F. Presotto; B. Pedini; L. Moro; R. S. Slack; F. Zanette; R. Zanche 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 530 KB

To evaluate the behaviour and predictive value of islet cell and insulin autoantibodies in patients with organ-specific autoimmune diseases, we followed 21 non-diabetic subjects for a mean period of 84 +/- 27 months. Ten patients were persistently seropositive for complement-fixing islet cell antibo